Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Apr;62(4):388–390. doi: 10.1136/jnnp.62.4.388

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study.

D S Molenaar 1, P A van Doorn 1, M Vermeulen 1
PMCID: PMC1074099  PMID: 9120456

Abstract

Six cycles of dexamethasone (40 mg per day for four sequential days) every 28 days induced remissions in 10 patients with idiopathic thrombocytopenic purpura (ITP). Whether the same results could be achieved in 10 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was investigated by comparing the Rivermead mobility index (RMI) before and after six cycles of treatment. Three patients discontinued treatment: one because of severe nausea and vomiting and two because of neurological deterioration. All seven patients who completed treatment improved on the RMI. One of these patients had a relapse within two months after the last cycle and six patients were in remission six months after the last dexamethasone cycle. Pulsed high dose dexamethasone induced remissions ranged from at least 15 to 23 months. This treatment needs to be tested against standard treatment in a randomised study.

Full text

PDF
388

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen J. C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994 Jun 2;330(22):1560–1564. doi: 10.1056/NEJM199406023302203. [DOI] [PubMed] [Google Scholar]
  2. Barohn R. J., Kissel J. T., Warmolts J. R., Mendell J. R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989 Aug;46(8):878–884. doi: 10.1001/archneur.1989.00520440064022. [DOI] [PubMed] [Google Scholar]
  3. Collen F. M., Wade D. T., Robb G. F., Bradshaw C. M. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud. 1991 Apr-Jun;13(2):50–54. doi: 10.3109/03790799109166684. [DOI] [PubMed] [Google Scholar]
  4. Donaghy M., Mills K. R., Boniface S. J., Simmons J., Wright I., Gregson N., Jacobs J. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994 Jul;57(7):778–783. doi: 10.1136/jnnp.57.7.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dyck P. J., Daube J., O'Brien P., Pineda A., Low P. A., Windebank A. J., Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986 Feb 20;314(8):461–465. doi: 10.1056/NEJM198602203140801. [DOI] [PubMed] [Google Scholar]
  6. Dyck P. J., Lais A. C., Ohta M., Bastron J. A., Okazaki H., Groover R. V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 Nov;50(11):621–637. [PubMed] [Google Scholar]
  7. Dyck P. J., Litchy W. J., Kratz K. M., Suarez G. A., Low P. A., Pineda A. A., Windebank A. J., Karnes J. L., O'Brien P. C. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994 Dec;36(6):838–845. doi: 10.1002/ana.410360607. [DOI] [PubMed] [Google Scholar]
  8. Dyck P. J., O'Brien P. C., Oviatt K. F., Dinapoli R. P., Daube J. R., Bartleson J. D., Mokri B., Swift T., Low P. A., Windebank A. J. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982 Feb;11(2):136–141. doi: 10.1002/ana.410110205. [DOI] [PubMed] [Google Scholar]
  9. Vermeulen M., van Doorn P. A., Brand A., Strengers P. F., Jennekens F. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36–39. doi: 10.1136/jnnp.56.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Vermeulen M., van der Meché F. G., Speelman J. D., Weber A., Busch H. F. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci. 1985 Oct;70(3):317–326. doi: 10.1016/0022-510x(85)90173-x. [DOI] [PubMed] [Google Scholar]
  11. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  12. van Doorn P. A., Vermeulen M., Brand A., Mulder P. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991 Feb;48(2):217–220. doi: 10.1001/archneur.1991.00530140113024. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES